# TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

> **NCT00146211** · PHASE3 · COMPLETED · sponsor: **Amarin Neuroscience Ltd** · enrollment: 300 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** Ethyl-EPA (Miraxion™)

## Key facts

- **NCT ID:** NCT00146211
- **Lead sponsor:** Amarin Neuroscience Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-08
- **Final completion:** 2007-07
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2007-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146211, "TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00146211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*